查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589053

结合疫苗市场：按类型、适应症、病原体类型、最终用户划分 - 2025-2030 年全球预测

Conjugate Vaccine Market by Type (Monovalent, Multivalent), Indication (Diphtheria & Pertussis, Influenza, Meningococcal), Pathogen Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年结合疫苗市场规模为396.7亿美元，预计2024年将达439.2亿美元，复合年增长率为10.81%，2030年将达814.2亿美元。

结合疫苗对于预防脑膜炎、肺炎和 b 型流感嗜血桿菌 (Hib) 等侵袭性疾病至关重要，透过将多醣抗原与蛋白质载体结合，可以提高免疫抗原性，尤其是在幼儿中。它的需求源自于其产生持久免疫反应和群体免疫、降低疾病发生率的能力。典型应用包括针对容易罹患某些感染疾病的婴幼儿、幼儿和成人的疫苗接种计划。最终用途包括医院、诊所、公共卫生机构、研究组织等。关键的成长要素包括对疫苗可预防疾病的认识提高、政府免疫措施以及疫苗开发的技术进步。医疗保健基础设施的持续投资以及更严格的医疗政策对儿科疫苗的需求增加为市场提供了支撑。 COVID-19 大流行也凸显了疫苗的重要性，并提高了市场对预防性医疗保健的整体关注。疫苗接种率低的地区也有新的商机，凸显市场拓展潜力。研发策略联盟可以推动创新并最大限度地提高市场渗透率。然而，对疫苗开发的犹豫、供应链中断以及疫苗开发成本上升等限制因素可能会阻碍成长。严格的监管环境需要广泛的临床评估，这带来了额外的挑战。创新可能会在开发耐热疫苗、新型佐剂系统以及同时针对多种病原体的组合疫苗方面取得进展。探索新的结合机制和替代载体蛋白可以提高功效并扩大保护范围。该市场仍然竞争激烈，重点是生物技术公司、全球卫生组织和政府机构之间的合作，以扩大疫苗的供应。透过在疫苗设计中利用人工智慧和机器学习等最尖端科技，公司可以优化疫苗效率并应对新出现的病原体挑战，从而成为该领域的领导者。

主要市场统计
基准年[2023] 396.7亿美元
预测年份 [2024] 439.2亿美元
预测年份 [2030] 814.2亿美元
复合年增长率（%） 10.81%

市场动态：快速发展的结合疫苗市场的关键市场洞察

供给和需求的动态交互作用正在改变结合疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 感染疾病和免疫抑制盛行率增加
    • 癌症治疗疫苗的采用增加
    • 世卫组织增加疫苗接种推广计划
  • 市场限制因素
    • 偏远地区疫苗取得困难
  • 市场机会
    • 政府努力提高人们对感染疾病的认识
    • 新型结合疫苗生产技术的进展
  • 市场挑战
    • 结合疫苗生产程序的复杂性

波特五力：驾驭结合疫苗市场的策略工具

波特的五力框架是了解结合疫苗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对结合疫苗市场的影响

外部宏观环境因素在塑造结合疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解联合疫苗市场的竞争状况

对结合疫苗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵结合疫苗市场供应商绩效评估

FPNV定位矩阵是评估结合疫苗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了结合疫苗市场的成功之路

结合疫苗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病增加和免疫抑制
      • 癌症治疗疫苗的采用增加
      • 世卫组织增加疫苗接种推广计划
    • 抑制因素
      • 偏远地区获得疫苗的机会很少
    • 机会
      • 政府努力提高人们对感染疾病的认识
      • 新型结合疫苗生产技术进展
    • 任务
      • 结合疫苗生产程序的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章结合疫苗市场：依类型

  • 单价
  • 多效价的

第七章 结合疫苗市场适应症

  • 白喉和百日咳
  • 流感
  • 脑膜炎奈瑟菌
  • 肺炎球菌

第八章以病原体类型分類的结合疫苗市场

  • 细菌结合疫苗
  • 联合结合疫苗
  • 病毒结合疫苗

第九章结合疫苗市场：依最终用户分类

  • 成人
  • 孩子们

第10章美洲结合疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太结合疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第12章：欧洲、中东和非洲结合疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bavarian Nordic
  • Bharat Biotech Ltd.
  • Bio-Med Limited
  • Biological E. Limited
  • Biological E. Ltd
  • CSL Limited
  • GlaxoSmithKline, plc.
  • Merck and Company
  • Novartis AG
  • Nuron Biotech Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur US, LLC
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Limited
  • Vaxcyte, Inc.
Product Code: MRR-433AB1DC2901

The Conjugate Vaccine Market was valued at USD 39.67 billion in 2023, expected to reach USD 43.92 billion in 2024, and is projected to grow at a CAGR of 10.81%, to USD 81.42 billion by 2030.

Conjugate vaccines are critical in preventing invasive diseases like meningitis, pneumonia, and Haemophilus influenzae type b (Hib) by linking polysaccharide antigens to protein carriers, enhancing immunogenicity, especially in young children. Their necessity stems from their ability to generate long-lasting immune responses and herd immunity, reducing disease incidence. Applications mainly include immunization programs targeting infants, young children, and adults with higher susceptibility to certain infectious diseases. End-use scope encompasses hospitals, clinics, public health agencies, and research institutions. Key growth influencers include heightened awareness of vaccine-preventable diseases, government immunization initiatives, and technological advancements in vaccine development. The market is buoyed by persistent investments in healthcare infrastructure and rising demand for pediatric vaccines due to stricter healthcare policies. The COVID-19 pandemic has also underscored the significance of vaccines, broadening the overall market focus on preventive healthcare. Emerging opportunities lie in geographical regions with low immunization coverage, highlighting the potential for expanding market footprints. Strategic collaborations in research and development sectors can propel technological innovations, maximizing market access. However, limitations such as vaccine hesitancy, supply chain disruptions, and high costs of vaccine development could impede growth. Stringent regulatory landscapes requiring extensive clinical evaluations pose additional challenges. Innovation can thrive in the development of thermostable vaccines, novel adjuvant systems, and combination vaccines that address multiple pathogens simultaneously. Exploring new mechanisms of conjugation and alternative carrier proteins can enhance efficacy and broaden protective scope. The nature of the conjugate vaccine market remains highly competitive, with a focus on partnerships between biotech firms, global health bodies, and governmental agencies to expand vaccine accessibility. By leveraging cutting-edge technologies like AI and machine learning in vaccine design, companies can optimize vaccine efficiency and target new pathogenic challenges, positioning themselves as leaders in the field.

KEY MARKET STATISTICS
Base Year [2023] USD 39.67 billion
Estimated Year [2024] USD 43.92 billion
Forecast Year [2030] USD 81.42 billion
CAGR (%) 10.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Conjugate Vaccine Market

The Conjugate Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of infectious diseases and immunosuppression
    • Rising adoption of cancer therapeutic vaccines
    • Rising number programs to promote vaccination by WHO
  • Market Restraints
    • Low accessibility to vaccines in remote areas
  • Market Opportunities
    • Government initiatives spreading awareness about infectious diseases
    • Advancement in technology for producing novel conjugate vaccines
  • Market Challenges
    • Complexity of production procedure of conjugate vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Conjugate Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Conjugate Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Conjugate Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Conjugate Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Conjugate Vaccine Market

A detailed market share analysis in the Conjugate Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Conjugate Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Conjugate Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Conjugate Vaccine Market

A strategic analysis of the Conjugate Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Conjugate Vaccine Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic, Bharat Biotech Ltd., Bio-Med Limited, Biological E. Limited, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur U.S., LLC, Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Vaxcyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Conjugate Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monovalent and Multivalent.
  • Based on Indication, market is studied across Diphtheria & Pertussis, Influenza, Meningococcal, and Pneumococcal.
  • Based on Pathogen Type, market is studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.
  • Based on End-User, market is studied across Adults and Children.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
      • 5.1.1.2. Rising adoption of cancer therapeutic vaccines
      • 5.1.1.3. Rising number programs to promote vaccination by WHO
    • 5.1.2. Restraints
      • 5.1.2.1. Low accessibility to vaccines in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives spreading awareness about infectious diseases
      • 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of production procedure of conjugate vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Conjugate Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent
  • 6.3. Multivalent

7. Conjugate Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Diphtheria & Pertussis
  • 7.3. Influenza
  • 7.4. Meningococcal
  • 7.5. Pneumococcal

8. Conjugate Vaccine Market, by Pathogen Type

  • 8.1. Introduction
  • 8.2. Bacterial Conjugate Vaccine
  • 8.3. Combination Conjugate Vaccine
  • 8.4. Viral Conjugate Vaccine

9. Conjugate Vaccine Market, by End-User

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Children

10. Americas Conjugate Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Conjugate Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Conjugate Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bavarian Nordic
  • 2. Bharat Biotech Ltd.
  • 3. Bio-Med Limited
  • 4. Biological E. Limited
  • 5. Biological E. Ltd
  • 6. CSL Limited
  • 7. GlaxoSmithKline, plc.
  • 8. Merck and Company
  • 9. Novartis AG
  • 10. Nuron Biotech Inc.
  • 11. Pfizer, Inc.
  • 12. Sanofi Pasteur U.S., LLC
  • 13. Serum Institute of India Pvt. Ltd.
  • 14. Taj Pharmaceuticals Limited
  • 15. Vaxcyte, Inc.

LIST OF FIGURES

  • FIGURE 1. CONJUGATE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. CONJUGATE VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONJUGATE VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023